Jefferies upgrades Cipla, Dr. Reddy's to 'hold' on resilient core business, valuations
RDY•Jefferies upgraded Cipla and Dr. Reddy's Laboratories to “hold,” citing resilient core businesses and valuations. The brokerage named Ajanta Pharma and Torrent Pharmaceuticals its top picks.
1. Ratings and top picks
Jefferies upgraded Cipla and Dr. Reddy's Laboratories to “hold,” citing resilient core businesses and valuations, and named Ajanta Pharma and Torrent Pharmaceuticals as its top pharma picks. It said Indian pharma demand remains robust, with Torrent and Zydus Lifesciences leading growth, while Dr. Reddy's leads sequential North American growth, aided by limited-competition launches and improving U.S. trends.
2. Sector performance
Domestic business strength continues to support earnings despite mixed margin trends across the sector. Year to date, Cipla shares were down 6% and Dr. Reddy's were up 10%; Torrent and Ajanta were up 21% and 19%, respectively. The pharma index was up 25%, while the Nifty 50 was down 2.3%.




